January 13, 2010 - Whole brain radiotherapy (WBRT) is often recommended for patients with advanced cancer to receive quick access to palliative radiotherapy.

A recent study published in the International Journal of Radiation Oncology Biology Physics found that physicians referring patients with brain metastases for consideration of WBRT are often overly optimistic when estimating the clinical benefit of the treatment and overestimate patient survival.

The primary objective of the study was to determine what are physician’s expectations of treatment outcomes for patients with brain metastases referred for whole brain radiotherapy (WBRT). As a secondary objective, researchers were trying to understand what factors influence the expectations and to determine the accuracy of the physician-estimated patient survival.

Of the nearly 80 referring physicians surveyed, more than 94.9 percent said they believed WBRT would stabilize neurologic symptoms, improve quality of life, and allow for a Decadron (dexamethasone) taper; 87.0 percent said WBRT would improve performance status; 77.9 percent expected it to improve neurologic symptoms; and 40.8 percent thought it would improve survival. While the actual survival patient survival was a median of two and a half months, the referring physicians estimated patient survival rates would reach six months on average. This discrepancy represented a median individual difference of 1.9 months.

This led researchers to conclude referring physicians’ expectations of WBRT outcomes are often overly optimistic, the physicians tend to over estimate patient survival, and more education and research in this field is needed.

Reference: Barnes, EA; Chow, E; Tsao, MN; Bradley, NM; Doyle, M; Li, K; Lam, K; Danjoux, C. Physician Expectations of Treatment Outcomes for Patients With Brain Metastases Referred for Whole Brain Radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):187-192.


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now